What Is the Optimal Dose and Schedule for Dasatinib in Chronic Myeloid Leukemia: Two Case Reports and Review of the Literature.

Oncology Research
Caroline JamisonMehmet Sitki Copur

Abstract

Efficacy and safety of dasatinib in chronic phase (CP) chronic myelogenous leukemia (CML) patients has been well established. Initially approved dose and schedule of 70 mg twice daily has been changed to 100 mg once daily after demonstration of the same efficacy with less toxicity. Some patients require significant dose reductions to enable continued treatment with dasatinib. Even at a dose of 80 mg once daily, several patients may require further dose reductions due to substantial toxicity while maintaining good control of their disease. We report two CP-CML patients achieving and maintaining major molecular responses while on very low doses of dasatinib, ultimately achieving undetectable levels of BCR-ABL fusion transcript in their peripheral blood. Observations of several CP-CML cases responding remarkably well to dasatinib despite very low dose and frequent dose interruptions challenge our current understanding and the accuracy of the data regarding the optimum dose and schedule of this drug. In selected intolerant patients, low-dose dasatinib therapy may be a safe and effective alternative treatment option before a treatment discontinuation or change considered.

References

Jan 29, 1999·Journal of the National Cancer Institute·P le CoutreC Gambacorti-Passerini
Apr 29, 1999·The New England Journal of Medicine·C L Sawyers
Jul 17, 2004·Science·Neil P ShahCharles L Sawyers
Jun 3, 2005·Annals of Hematology·Rüdiger HehlmannAndreas Hochhaus
Aug 27, 2005·Clinical Pharmacokinetics·Bin PengHorst Schran
Jun 16, 2006·The New England Journal of Medicine·Moshe TalpazCharles L Sawyers
Jul 14, 2006·Mayo Clinic Proceedings·Alfonso Quintás-Cardama, Jorge E Cortes
Feb 23, 2007·Drugs of Today·Neil P Shah
Jan 29, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael BraveRichard Pazdur
Jun 11, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Neil P ShahAndreas Hochhaus
Feb 25, 2009·Journal of Hematology & Oncology·Siu-Fun Wong
Aug 27, 2009·Blood·Jennifer L SneadMichael W Deininger
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David MarinJamshid S Khorashad

❮ Previous
Next ❯

Citations

Sep 25, 2016·Seminars in Oncology·Ralph E Parchment, James H Doroshow
Aug 18, 2016·Toxicon : Official Journal of the International Society on Toxinology·Angelica Rocio Bonilla-PorrasCarlos Velez-Pardo
Jan 26, 2018·Cancer·Moshe TalpazPhilippe Rousselot
Nov 24, 2018·BMC Cancer·Faouzi DjebbariVerna Teresa Lavender
Feb 21, 2019·Experimental and Therapeutic Medicine·Jun GuoFanjun Meng

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Related Concepts

Related Feeds

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.